May 8th 2024
For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Mirvetuximab Soravtansine Remains Well Tolerated in Platinum-Resistant Ovarian Cancer
November 15th 2019Kathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha–positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.
Watch
More Frontline PARP Indications Are Expected in Ovarian Cancer
November 8th 2019PARP inhibitors are increasingly relevant for frontline maintenance indications and potentially in combination with chemotherapy for treatment-naïve ovarian cancer, including for those with <em>BRCA</em>-wildtype disease, Leslie M. Randall, MD, said to the audience at the <em>37th Annual</em> CFS.
Read More
A Look Back at FDA News from October 2019
November 1st 2019In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.
Read More
FDA Approves Niraparib for Previously Treated HRD+ Advanced Ovarian Cancer
October 23rd 2019The FDA has approved niraparib for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with ≥3 prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency positivity.
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer
October 9th 2019The case for the combination of olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, which was covered in 2 separate presentations at the 2019 ESMO Congress.
Read More
Rationale for Chemotherapy Plus Veliparib in Frontline Treatment of Ovarian Cancers
October 8th 2019Robert L. Coleman, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, explains the rationale for the VELIA trial of veliparib with frontline chemotherapy and maintenance in patients with high-grade ovarian cancer.
Watch
Experts in Oncology Highlight Key Abstracts Presented at the 2019 ESMO Congress
October 7th 2019Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Overall, the abstracts presented at this year’s meeting will change the treatment paradigm in a number of patient populations.
Read More
FDA Fast Track Designation Granted to Navicixizumab for Heavily Pretreated Ovarian Cancer
October 7th 2019The FDA has granted a fast track designation to navicixizumab for the treatment of patients with high-grade ovarian, primary peritoneal, or fallopian tube cancer who have received ≥3 prior therapies and/or prior bevacizumab.
Read More
Trametinib Benefit Promising for Recurrent, Low Grade Ovarian Cancer
October 5th 2019In a randomized trial, treatment with MEK inhibitor trametinib showed significant improvement in progression-free survival and overall survival in patients with recurrent, low-grade serous ovarian cancer.<br />
Read More
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
VELIA Trial Shows Benefit for Combination of PARP Plus Chemotherapy in Ovarian Cancer
October 4th 2019Patients with high-grade serous ovarian cancer experienced a 32% reduction in the risk of progression or death with frontline combination veliparib plus carboplatin and paclitaxel followed by veliparib maintenance, according to the data from the phase III VELIA trial presented at the 2019 ESMO Congress, and simultaneously published in the New England Journal of Medicine.
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Olaparib Plus Bevacizumab Extends PFS as Frontline Maintenance in Ovarian Cancer
September 28th 2019The combination of olaparib and bevacizumab as frontline maintenance improved the median progression-free survival by 5.5 months over bevacizumab and placebo in patients with newly diagnosed, advanced ovarian cancer following prior treatment with a platinum-based chemotherapy plus bevacizumab, according to the phase III PAOLA-1 findings presented at the 2019 ESMO Congress.
Read More
PFS Improved With Frontline Niraparib Maintenance in Ovarian Cancer
September 28th 2019Median progression-free survival was improved by 5.6 months with PARP inhibitor niraparib as first-line treatment for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy compared with placebo, according to data from the phase III PRIMA study presented at the ESMO Congress 2019 and simultaneously published in the <em>New England Journal of Medicine</em>.
Read More
Combination Cediranib Plus Olaparib Improves PFS in Platinum-Resistant Ovarian Cancer
September 28th 2019Cediranib in combination with olaparib demonstrated an improvement in progression-free survival when used as treatment for patients with platinum-resistant ovarian cancer (PROC). However, the difference in PFS compared with chemotherapy did not achieve statistical significance, according to a randomized trial presented at the 2019 ESMO Congress.
Read More
Phase III PRIMA Trial Shows PFS Benefit With Niraparib as First-Line Maintenance in Ovarian Cancer
July 15th 2019In the phase III PRIMA trial, niraparib demonstrated a benefit in progression-free survival compared with placebo when used as maintenance therapy following platinum-based chemotherapy for patients with ovarian cancer treated in the first line. The PFS benefit was found to be statistically significant, regardless of patients’ biomarker status, meeting the primary endpoint of the trial.
Read More